Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Jazz Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Takeda Oncology.

Advances in™ ALL: Optimal Use and Sequencing of Novel Agents Across Lines of Care

Release Date: January 31, 2020
Expiration Date: January 31, 2021
Media: Internet - based

Activity Overview

Advances in™ ALL: Optimal Use and Sequencing of Novel Agents Across Lines of Care is an online activity featuring expert commentary regarding current and emerging treatment for acute lymphoblastic leukemia (ALL). Elias Jabbour, MD, is a professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas (UT) MD Anderson Cancer Center in Houston, Texas. During this online program, he answers important questions and offers his perspectives on the clinical management of pediatric and adult ALL in the frontline and relapsed/refractory (R/R) settings.

Benefits of Participating

  • Be better able to identify patients presenting with ALL.
  • Refresh your knowledge on risk stratification in ALL.
  • Learn about clinical data from ongoing studies.
  • Be more confident in your clinical decisions for pediatric and adult patient populations with ALL.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Jazz Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational program is directed toward hematologists and medical oncologists interested in the treatment of ALL. Other allied healthcare professionals, including nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment of patients with ALL, will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Outline risk stratification strategies in ALL to help develop appropriate treatment plans through cytogenetic and immunophenotypic studies.
  • Select novel therapeutic options in the frontline and R/R settings and optimize the selection and sequencing of treatment options.
  • Summarize the role of emerging therapies for the management of ALL.
  • Evaluate groups of patients who may be eligible for emerging ALL treatment approaches.

Faculty, Staff, and Planners’ Disclosures


Elias Jabbour
Elias Jabbour, MD
Professor, Department of Leukemia
UT MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Amgen, Pfizer, Takeda, Adaptive, Novartis, Spectrum, AbbVie, BMS.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By